The MarketWatch News Department was not involved in the creation of this content. -- Non-exclusive license allows for development by Pfizer to utilize Matrix-M(R) for up to two disease areas with its ...

Novavax faces plenty of uncertainty related to a deal it signed with a larger company. The biotech's pipeline doesn't look that exciting either. Last year, Novavax signed an agreement with Sanofi, ...

Novavax, Inc. (NASDAQ: NVAX) shares are trading higher Tuesday after the company announced it entered into a license agreement with Pfizer, Inc. (NYSE: PFE) for use of its Matrix-M adjuvant. Under the ...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

Novavax (NVAX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the ...

GAITHERSBURG, Md., Jan. 20, 2026 /PRNewswire/ -- Novavax, Inc. has entered into a license agreement with Pfizer for use of Novavax's Matrix-M ® adjuvant. Under the terms of the agreement, Pfizer will ...